reSee.it - Related Video Feed

CMS is currently offering a 20% bonus payout to hospitals that choose to use Remdesivir for Medicare aged patients. This drug is supposedly approved by the FDA and recommended by the NIH for COVID-19 treatment. However, it is known to cause kidney, heart, and liver failure. Hospitals are also being incentivized to PCR test every patient, regardless of the reason for their visit, in order to increase their numbers. The federal government pays a monthly bribe based on the percentage of PCR tests conducted. Hospitals receive a 20% bonus for every positive COVID-19 diagnosis, as well as for using Remdesivir and ventilating patients. Additionally, they receive further incentives for every COVID-19 death, amounting to $9,000 per case per month. The reasons behind these incentives remain unclear.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug for 5 to 10 days in hospitals. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir is cardiotoxic and can cause death of heart cells. Despite this, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients. The World Health Organization published in April of last year that Remdesivir leads to increased acute kidney failure compared to other drugs. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

At home, it is recommended to treat viral replication by giving zinc and other remedies like hydroxychloroquine and ivermectin. However, the protocol followed was to provide no treatment until hospitalization. Once in the hospital, the treatment included ventilators and Remdesivir. It is claimed that Tony Fauci knew Remdesivir could be lethal, as it had caused harmful side effects in Ebola patients. The drug was then used in the pandemic, leading to kidney failure, heart failure, and organ collapse in those who died. The deaths were attributed to Remdesivir rather than the virus itself.

Treat COVID-19 at home with zinc and zinc-enhancing remedies like hydroxychloroquine and ivermectin, which reduce viral spread. Current protocol delays treatment until hospitalization, using ventilators and remdesivir, known to cause harm. Fauci's promotion of remdesivir, despite its lethal side effects, led to unnecessary deaths from kidney and heart failure. The true cause of death during the pandemic was not the virus but remdesivir.

At home, it is recommended to treat viral replication by giving remedies like zinc and hydroxychloroquine, ivermectin, which reduce the spread of the disease. However, the protocol followed was different. No treatment was given until hospitalization, where ventilators and Remdesivir were used. It is known that Remdesivir can be harmful, as it caused side effects in Ebola patients. The drug was manipulated and made standard of care, leading to kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths during the pandemic were often attributed to kidney failure, which was caused by Remdesivir, not the virus itself.

Since May 2020, Remdesivir has been linked to a 30% death rate among patients receiving the drug in hospitals for 5 to 10 days. In New York, 26.9% of Medicare-aged patients who received Remdesivir died. The Cardiovascular Toxicology Journal found in October 2020 that Remdesivir causes heart cell death and is cardiotoxic. However, the FDA and NIH continue to approve and recommend Remdesivir as the only drug for hospitalized COVID-19 patients, despite the World Health Organization's report in April of last year that it causes increased acute kidney failure. Shockingly, the FDA recently authorized the use of Remdesivir for newborns and children up to 18 years old.

Since May 2020, remdesivir may result in at least 30% death in hospitalized patients who receive it for five to ten days. CMS data for Medicare patients in New York showed 26.9% of those who received remdesivir died. In October 2020, the cardiovascular toxicology journal found remdesivir causes death of heart cells, is cardiotoxic, and can lead to cardiac arrest. Despite this, in December 2020, the NIH, with Anthony Fauci, updated guidelines listing remdesivir as the only FDA-approved drug for hospitalized Americans, even though the WHO published data in April of last year that it increases acute kidney failure compared to other drugs used to treat COVID-19. As of January 21st of this year, the FDA extended emergency use authorization, making remdesivir the only authorized medication that can be administered intravenously to newborns to 18-year-olds for COVID-19.

Before the pandemic, Dr. Fauci tested Remdesivir in an Ebola trial in Africa alongside four other drugs. However, the institutional review board (IRB), responsible for ensuring safety in clinical trials, intervened and removed Remdesivir from the trial due to its high fatality rate. Ebola typically kills 53% of those infected, but Remdesivir was causing even more deaths. It seems illogical to then administer this drug to individuals with a disease that has a much lower infection fatality rate of 1%. This decision appears questionable, but unfortunately, there is a history of similar actions being taken.

There are numerous studies showing the significant benefits of Ivermectin, with a 70 to 85% reduction in hospitalizations and deaths. It has been effective worldwide, including in countries like Nigeria, which has the highest burden of river blindness but the lowest COVID death rate. They use both Ivermectin and hydroxychloroquine. Similarly, states in India like Kerala and Uttar Pradesh had comparable death rates by following a protocol that included Ivermectin and hydroxychloroquine. There are over 400 studies supporting the benefits of hydroxychloroquine and nearly 100 studies showing the devastating benefits of Ivermectin. However, a few government-produced studies financed by Bill Gates and the WHO claim no benefit, but these studies have been criticized.

Ivermectin is extremely safe, arguably safer than a sugar pill. In a randomized trial, those taking Ivermectin daily would likely experience fewer health issues than those on sugar pills. The narrative labeling Ivermectin as a toxic horse dewormer is misleading; over 3.7 billion doses have been administered to humans. It has significantly impacted global health by nearly eradicating several parasitic diseases. In fact, the risk of death from Tylenol is higher than from Ivermectin. While there are debates about its efficacy, in situations with limited options, using a safe and inexpensive drug like Ivermectin for sick patients seems reasonable.

Over 100 studies have shown that Ivermectin has had significant benefits, reducing hospitalizations and deaths by 70 to 85%. It was effective worldwide, including in Nigeria, where they used it for river blindness and had the lowest COVID death rate. Similarly, states in India like Kerala and Uttar Pradesh used our protocol with Ivermectin and hydroxychloroquine, ending the pandemic overnight. There are around 400 studies supporting the benefits of hydroxychloroquine and nearly 100 studies showing the devastating benefits of Ivermectin. However, a few government-produced studies financed by Bill Gates and the WHO claim no benefit, but these studies have been criticized.

Treating viral replication at home can be done with zinc and zinc-enhancing remedies like hydroxychloroquine and ivermectin. However, the protocol followed during the pandemic did not include these treatments. Instead, patients were only treated when they reached the hospital, where they were given ventilators and Remdesivir. It is known that Remdesivir can be lethal, as it caused kidney failure, heart failure, and organ collapse in many cases. The deaths during the pandemic were often attributed to kidney failure, which was actually caused by Remdesivir, not the virus itself.

Speaker 0: There were four drugs that were being tested for Ebola. Remdesivir killed more people than placebo, and the data safety monitoring board had actually stopped the study where literally fifty three percent of Speaker 1: the patients died in the failed Ebola trial and was repurposed. It was a failed Ebola drug because it caused more harm than good in Ebola trials. It was still unpatent. It was Tony Fauci's drug of choice. The majority of hospital deaths were actually caused by Anthony Fauci because his NIH put out protocols that if the hospital systems adhered to, they got bonuses, big bonuses, lots of money, $3,000 per for putting an IV in of remdesivir. Boom. $3,000. But guess what? On top of the entire hospital stay, a 20% bonus, that could be hundreds of thousands of dollars. Speaker 0: The data was so overwhelming that remdesivir killed patients more so than placebo. The drug had to be stopped, and this was published in the New England Journal in the 2019. Speaker 2: What happened during COVID could not have happened without propaganda and censorship. And how do we overcome that propaganda and censorship? It's primarily through people not being willing to shut up.

At home, it is recommended to treat viral replication by giving zinc and other zinc-enhancing remedies like hydroxychloroquine and Ivermectin. However, the protocol followed by hospitals was to provide no treatment until admission, and then use ventilators and Remdesivir, which were known to be harmful. Tony Fauci was aware of the dangers of Remdesivir, as it caused lethal side effects in Ebola patients. Despite this, he manipulated a study to make Remdesivir the standard of care, resulting in kidney failure, heart failure, and organ collapse in COVID-19 patients. The deaths attributed to the virus were actually caused by Remdesivir.

To treat viral infections at home, zinc and its enhancers, like hydroxychloroquine and ivermectin, should be used, as they significantly reduce disease spread. However, the established protocol delayed treatment until hospitalization, where patients received ventilators and remdesivir—both potentially lethal. Remdesivir had previously shown harmful effects in Ebola trials, leading to its discontinuation due to a high rate of severe side effects. Despite this, it became standard care during the pandemic, contributing to kidney failure, heart failure, and organ collapse in patients. Many who died were reported to have kidney failure, which was not caused by the virus but rather by the effects of remdesivir.

Dr. Ryan Cole, a pathologist and expert in immunology and virology, discusses the use of Ivermectin as a treatment for COVID-19. He highlights that if Ivermectin is added to the treatment, it can decrease the death rate by 75% if administered early. However, he criticizes the NIH for recommending against its use based on flawed data. Dr. Cole mentions that doctors in Texas, Florida, and Wisconsin have successfully used Ivermectin, reducing death rates by 70% to 90% in their hospitals. He also raises concerns about a conflict of interest between the federal government and vaccine companies, suggesting that they may not want an effective therapy to overshadow the vaccines.

Over 100 studies have shown that Ivermectin has had significant benefits, reducing hospitalizations and deaths by 70 to 85%. It has been widely used around the world, including in Nigeria, where it helped lower the COVID death rate. Kerala and Uttar Pradesh states in India also used Ivermectin and hydroxychloroquine, effectively ending the pandemic. Numerous studies, including 400 on hydroxychloroquine and nearly 100 on Ivermectin, demonstrate their benefits. However, a few government-funded studies, including those by the WHO and financed by Bill Gates, claim no benefits but have been criticized for their methodology. For more information, you can visit the websites of Dr. Meryl Masse or Yale epidemiologist Harvey Riesch.

CMS is currently offering a 20% bonus payout to hospitals that choose to use remdesivir for all Medicare aged patients. This drug is supposedly approved by the FDA and recommended by the NIH for COVID-19 treatment. However, it is known to cause kidney, heart, and liver failure. Hospitals are also being incentivized to PCR test every patient, regardless of the reason for their visit, and are paid a bribe for the percentages of positive COVID-19 diagnoses. Additionally, hospitals receive a 20% bonus for using remdesivir, ventilating patients, and for every COVID-19 death, earning up to $9,000 per case per month. The reasons behind these incentives remain unclear.

The forest plot shows COVID medicines, with only expensive ones approved in the US. Cheaper drugs were ignored. Studies manipulated endpoints and faced negative PR. Over 420 trials on hydroxychloroquine and 100 on Ivermectin show significant benefits, but they are dismissed in the US.

Treating viral infections at home can be done by providing remedies that inhibit viral replication, such as zinc and substances that enhance zinc like hydroxychloroquine and ivermectin. However, the protocol followed during the pandemic did not include these treatments. Instead, patients were only treated once they reached the hospital, where they were given ventilators and Remdesivir. It is known that Remdesivir can be lethal, as it caused kidney failure, heart failure, and organ collapse in many cases. The deaths attributed to the virus were often a result of Remdesivir rather than the virus itself.

Remdesivir, one of four drugs tested for Ebola, allegedly killed more people than the placebo, leading the Data Safety Monitoring Board to halt the study. According to the transcript, 53% of patients died in the failed Ebola trial, but the drug was repurposed. It is claimed that Remdesivir was Anthony Fauci's drug of choice, and that the NIH protocols, which provided hospitals with bonuses for using remdesivir, caused the majority of hospital deaths. Reportedly, hospitals received $3,000 for each remdesivir IV and a potential 20% bonus. The data allegedly showed that remdesivir killed more patients than the placebo, resulting in the drug trial being stopped. One speaker stated that it is inexplicable that remdesivir became the standard of care, and that doctors seemingly shut off their brains and followed directions from above without questioning the use of remdesivir in every hospitalized patient.

Treat COVID at home with zinc, hydroxychloroquine, ivermectin, and other remedies that reduce viral spread. Current protocol delays treatment until hospitalization, using harmful ventilators and remdesivir. Fauci knew remdesivir's dangers from Ebola trials. He manipulated data to make it standard care, causing kidney and heart failure. Many pandemic deaths were due to remdesivir, not the virus.

Patients were desperate for ivermectin as their loved ones died, but the focus shifted to remdesivir, a previously failed Ebola drug. By November 2020, the World Health Organization advised against its use, citing ineffectiveness and potential kidney and liver damage. The European Society of Critical Care supported this stance. Despite the warnings, the U.S. Health and Human Services incentivized hospitals with a 20% bonus for administering remdesivir, leading to widespread use. It failed to reduce mortality and caused serious injuries, with some patients dying as a result. In May 2022, the WHO reaffirmed its initial decision, stating that remdesivir should never have been used.

I've stated since May 2020 that remdesivir will result in at least 30% death in those who receive it in the hospital. I had data pulled for Medicare patients in New York, and found that 26.9% of those who received remdesivir died. As of October 2020, the cardiovascular toxicology journal found that remdesivir causes death of heart cells and can lead to cardiac arrest. Yet, in December, the NIH decided to update all guidelines for treatment drugs allowed for COVID-19, and remdesivir was the only FDA-approved drug for hospitalized Americans, despite the WHO publishing that it causes increased acute kidney failure. As of January of this year, the FDA extended an emergency use authorization, making remdesivir the only authorized medication that can be administered to newborns to 18-year-olds.

Conflicts and controversies surrounding remdesivir are significant. In November 2020, the World Health Organization conducted a comprehensive study and advised against using remdesivir in hospitals due to its association with death and kidney and liver injuries. Despite this, the U.S. incentivizes its use by offering hospitals a 20% bonus on the total bill if remdesivir is administered. As a doctor, I find it troubling that while other medications do not provide such financial incentives, the use of remdesivir can lead to substantial additional costs for hospitals, contradicting the WHO's recommendations. This situation highlights a serious disconnect in medical decision-making.